Dwarfism Medicine Shows Lure of $400,000 Rare-Disease Drugs

Dwarfism Medicine Shows Lure of $400,000 Rare-Disease Drugs

The U.S. and Europe give drugmakers exclusive marketing rights to focus on these so-called orphan diseases with no other treatment options, and smaller patient populations mean fewer participants are needed for clinical trials. Photograph: Getty Images